Description
Buy ADB-FUBINACA new online
Buy ADB-FUBINACA new online is a potent agonist for the cannabinoid receptors which first was discovered in 2013 in Japan in a smoking mixture. The enantiomer of this substancewas originally developed by Pfizer in 2009 as an analgesic medication, but was never pursued for human use. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group. In 2013, ADB-FUBINACA was identified in recreational products by Japanese forensic scientists.In Europe, it was first reported on 28 November 2013, in Turkey and Germany.
Its official designation in the IUPAC system is defined N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide , and simple chemical formula of the substance is summed up as , C20H21FN4O2 with the molecular weight determined to be 368.4 g/mol. The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.
ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013.The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.
An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.
